the words that we write walk into people's lives.

They are so hungry and so in need of these changes.

This is, as you said and have said many times, this is a devastating disease, and I don't think this can be treated as 17 months of a little additional hope.

We need to get a clear explanation from hospitals on why, after hospitals acquire physician practices, the prices for the services provided by the acquired physicians increases by 14 percent.

I find it hypocritical when I hear time and time and time again that plans are often blocked by PBMs from offering the lowest-priced generic.

I think that the committee needs to take that into consideration.

I see, as I expressed to you when we spoke, a disconnect between CMS, the FDA, and the VA on new treatments for mild Alzheimer's.

I think that, you know, to a person--well, maybe not to a--well, just--I am getting myself in a little trouble here.

The Medicaid Value-Based Payments for Patients Act will codify a CMS rule to help ensure Medicaid enrollees have access to breakthrough gene therapies.

I fully support these bills.

You did a great job, and I think that you answered--with your answers you were highly instructive to all of the members of the committee.